Question
Tesaro is a biotech company developing ovarian cancer treatment. The company projects annual sales of $2,150M for 10 years, after which its patent will expire.
Tesaro is a biotech company developing ovarian cancer treatment. The company projects annual sales of $2,150M for 10 years, after which its patent will expire. It has an EBIT margin of 40%, spends $100M per year on capital expenditures and has $50M per year of depreciations in those 10 years and 0 after. Corporate tax rate is 20%. Risk free rate is 3.0%. Tesaros asset beta equals 1.3, and the market risk premium 8.0%. The company is all-equity financed. The number of shares outstanding is 55M.
A. Valuation. (i) Find the fair value of Tesaro.
(ii) At its current price of $44, is Tesaros stock over- or undervalued? Explain your answer
Step by Step Solution
There are 3 Steps involved in it
Step: 1
Get Instant Access to Expert-Tailored Solutions
See step-by-step solutions with expert insights and AI powered tools for academic success
Step: 2
Step: 3
Ace Your Homework with AI
Get the answers you need in no time with our AI-driven, step-by-step assistance
Get Started
The Legal Environment Today Summarized Case Edition
Authors: Roger LeRoy Miller
8th Edition
130526276X, 978-1305279407, 1305279409, 978-1305704930, 1305704932, 978-1305262768
